Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
1,3280
Trial Sponsor
Clinical Trial Start Date
2024
0Primary Completion Date
2026
0Study Completion Date
2026
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Interventional Trial Phase
Phase 30
Official Name
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia0
Last Updated
April 4, 2024
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Participant0
Outcomes Assessor0
Investigator0
Care Provider0
Other attributes
Intervention Treatment
Plozasiran Injection0
Placebo0
Study summary
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
